Everybody possesses a unique microbiome composed of trillions of bacteria that release nano-sized extracellular vesicles (EVs) throughout our body. After over a decade of research on the relationship between the microbial EVs in our bodies and chronic illness, we created a one-of-a-kind precision medicine platform to provide innovativesolutions to modern healthcare needs.
By harnessing the dynamic activity of the human microbiome,
we are developing drug and IVD pipelines with a strong foundational IPR.
We are exploring the therapeutic applications of human microbiota-derived extracellular vesicles (EVs) in cancer immunotherapy as well as range of indications including central nervous system (CNS), metabolic, allergic and respiratory diseases.View More
By analyzing the microbiome activity of thousands of clinical samples via extracellular vesicles (EVs), we are developing in vitro diagnostic (IVD) pipelines to assess disease risk for a breadth of cancers and chronic illnesses to provide healthcare providers with modern tools for 21st century medicine.View More
MD Healthcare’s core strength lies in our strong intellectual property right (IPR) as pioneers in the field of microbiome extracellular vesicle (EVs) research.
With over 50 international and domestic patents registered for the use of various microbial EVs for therapeutic and diagnostic applications.
Our Smart Healthcare platform analyzes your unique microbiome to navigate your disease risk and provide health foods personalized to fit your microbiome health promotion needs. All from the comfort of your home.
Send us your sample and we can analyze your personalmicrobiome to determine your risk for over a dozen chronic illnesses. Our AI-based algorithm utilizes samples from thousands of chronically ill patients to provide accurate results.Find out more
After navigating your microbiome health, explore the targeted health foods designed to reduce your individual disease risk. MD FIT™ products are made from high quality, natural ingredients scientifically determined to promote your microbiome balance.Find out more
Stay up to date on MD Healthcare’s business & research developments as well as our activity in the media.
MD Healthcare and Kolmar Korea signed a license agreement for joint development of its lead microbial EV therapeutic pipeline for inflammatory diseases and cancer in the Asian territory. This agreement will combine the microbiome research capabilities of MD Healthcare with the pharmaceutical expertise and know-how of Kolmar Korea.
For more information, click here.
December 15, 2020
Nano-sized extracellular vesicles (EVs) derived from probiotic Lactobacillus paracasei elicited an anti-inflammatory response in the intestines of colitis mice. The mechanism of action was shown to be attenuation of endoplasmic reticulum stress in intestinal epithelial cells.
For more information, read our article published in Nature EMM.
July 16, 2020
MD Healthcare was selected as a technology innovation task for the BIG3 field of SME innovative growth support project by the Korean Ministry of SMEs and Startups. The project will focus on pre-clinical development of our microbial EV asset MDH-101 for treatment of viral pneumonia as a novel therapeutic for COVID-19.
For more information, click here
November 30, 2020